Deregulated cell division, resulting in aberrant cell proliferation, is one of the key hallmarks of cancer. Cyclin-dependent kinases (CDKs) play a central role in cell cycle progression in cancer, and the clinical development of the CDK4/6 inhibitors palbociclib, ribociclib, and abemaciclib has changed clinical practice in the setting of endocrine-receptor positive breast cancer. Results of pivotal phase II and III trials investigating these CDK4/6 inhibitors in patients with endocrine receptor-positive, advanced breast cancer have demonstrated a significant improvement in progression-free survival, with a safe toxicity profile. No validated biomarkers of sensitivity or resistance exist at the moment. Future development of CDK4/6 inhibitors in breast cancer should focus on the identification of predictive biomarkers, the development of drug combinations to overcome resistance, and the application of CDK4/6 inhibitors to other breast cancer subtypes.
CITATION STYLE
Robert, M., Frenel, J. S., Bourbouloux, E., Rigaud, D. B., Patsouris, A., Augereau, P., … Campone, M. (2018, September 1). An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer. Drugs. Springer International Publishing. https://doi.org/10.1007/s40265-018-0972-9
Mendeley helps you to discover research relevant for your work.